Antihypertensive drugs and incidence of type 2 diabetes: Evidence and implications for clinical practice

Current Hypertension Reports

Volumn 7, Issue 5, 2005, Pages 314-322

  Asfaha, Samuel ^a   Padwal, Raj ^a  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ADIPONECTIN; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; ATENOLOL PLUS CHLORTALIDONE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUCOSE; INSULIN; LEPTIN; NATEGLINIDE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; POTASSIUM; RAMIPRIL; ROSIGLITAZONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DISEASE CONTROL; DOSE RESPONSE; DRUG ACTIVITY; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLYCEMIC LOAD; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOKALEMIA; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL CIRCULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; VASODILATATION;

EID: 27544511734     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-005-0063-7     Document Type: Review

References (52)

1. Centers for Disease Control and Prevention: National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2000. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2002.
2. Edelstein SL, Knowler WC, Bain RP, et al.: Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997, 46:701-710.
3. Wild S, Roglic G, Green A, et al.: Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
4. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374-381.
5. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
6. Padwal R, Laupacis A: Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004, 27:247-255.
7. Jandeleit-Dahm KA, Tikellis C, Reid CM, et al.: Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005, 23:463-473.
8. Janke J, Engeli S, Gorzelniak K, et al.: Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002, 51:1699-1707.
9. Sharma AM, Janke J, Gorzelniak K, et al.: Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002, 40:609-611.
10. Kon V, Jabs K: Angiotensin in atherosclerosis. Curr Opin Nephrol Hypertens 2004, 13:291-297.
11. Benson SC, Pershadsingh HA, Ho CI, et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993-1002.
12. Houston MC: The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J 1988, 115:640-656.
13. Trost BN, Weidmann P: Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: a review. J Hypertens Suppl 1987, 5:S81-S104.
14. Pitre M, Gaudreault N, Santure M, et al.: Isradipine and insulin sensitivity in hypertensive rats. Am J Physiol 1999, 276:E1038-E1048.
15. Wicklmayr M, Rett K, Dietze G, et al.: Effects of beta-blocking agents on insulin secretion and glucose disposal. Horm Metab Res Suppl 1990, 22:29-33.
16. Cerasi E, Luft R, Efendic S: Effect of adrenergic blocking agents on insulin response to glucose infusion in man. Acta Endocrinol (Copenh) 1972, 69:335-346.
17. Pollare T, Lithell H, Selinus I, et al.: Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989, 298:1152-1157.
18. Jacob S, Rett K, Henriksen EJ: Antihypertensive therapy and insulin sensitivity: Do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998, 11:1258-1265.
19. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989, 321:868-873.
20. Fajans SS, Floyd JC Jr, Knopf RF, et al.: Benzothiadiazine suppression of insulin release from normal and abnormal islet tissue in man. J Clin Invest 1966, 45:481-492.
21. Lake CR, Ziegler MG, Coleman MD, et al.: Hydrochlorothiazide-induced sympathetic hyperactivity in hypertensive patients. Clin Pharmacol Ther 1979, 26:428-432.
22. Harper R, Ennis CN, Heaney AP, et al.: A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 1995, 38:853-859.
23. Harper R, Ennis CN, Sheridan B, et al.: Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ 1994, 309:226-230.
24. Rowe JW, Tobin JD, Rosa RM, et al.: Effect of experimental potassium deficiency on glucose and insulin metabolism. Metabolism 1980, 29:498-502.
25. Gorden P, Sherman BM, Simopoulos AP: Glucose intolerance with hypokalemia: an increased proportion of circulating proinsulin-like component. J Clin Endocrinol Metab 1972, 34:235-240.
26. Helderman JH, Elahi D, Andersen DK, et al.: Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983, 32:106-111.
27. Carlsen JE, Kober L, Torp-Pedersen C, et al.: Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990, 300:975-978.
28. Padwal R, Majumdar SR, Johnson JA, et al.: A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005, 28:736-744.
29. Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-912.
30. Padwal R, Mamdani M, Alter DA, et al.: Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort. Diabetes Care 2004, 27:2458-2463.
31. Verdecchia P, Reboldi G, Angeli F, et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:963-969.
32. Savage PJ, Pressel SL, Curb JD, et al.: Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998, 158:741-751.
33. Fletcher A, Amery A, Birkenhager W, et al.: Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. J Hypertens 1991, 9:225-230.
34. Kostis JB, Wilson AC, Freudenberger RS, et al.: Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005, 95:29-35.
35. Yusuf S, Gerstein H, Hoogwerf B, et al.: Ramipril and the development of diabetes. JAMA 2001, 286:1882-1885.
36. Vermes E, Ducharme A, Bourassa MG, et al.: Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003, 107:1291-1296.
37. Braunwald E, Domanski MJ, Fowler SE, et al.: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004, 351:2058-2068.
38. Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
39. Lithell H, Hansson L, Skoog I, et al.: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875-886.
40. UK Prospective Diabetes Study Group: UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995, 44:1249-1258.
41. Staessen JA, Wang JG, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001, 358:1305-1315.
42. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527-1535.
43. Freemantle N, Cleland J, Young P, et al.: Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999, 318:1730-1737.
44. Heidenreich PA, Lee TT, Massie BM: Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997, 30:27-34.
45. Khan NA, McAlister FA, Campbell NR, et al.: The 2004 Canadian recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol 2004, 20:41-54.
46. Chobanian AV, Bakris GL, Black HF, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Hypertension 2003, 42:1206-1252.
47. Fox KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782-788.
48. Wolf-Maier K, Cooper RS, Kramer H, et al.: Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004, 43:10-17.
49. Appel LJ: The verdict from ALLHAT - thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002, 288:3039-3042.
50. Gerstein HC, Yusuf S, Holman R, et al.: Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004, 47:1519-1527.
51. Navigator press release. The NAVIGATOR study [article online]. Available from http://www.bioportfolio.com/news/novartis_2.htm. Accessed May 2005.
52. Yusuf S: From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002, 89(Suppl): 18A-26A.